Synopsis: Zydus Lifesciences reported strong FY26 growth with higher revenue and profit, while also announcing a 100 percent dividend on FV and ₹1,100 crore buyback at a 16% premium, reflecting confidence in its long-term business outlook.
This Large-Cap Pharma Stock, engaged in the research, development, manufacturing, and marketing of pharmaceutical formulations, biologics, vaccines, APIs, and healthcare products across global markets, jumped 5.78 percent after the company reported March quarterly results and announced a dividend of 100 percent on face value and also announced a Rs. 1,100 crore buyback.
With a market capitalization of Rs. 1,02,983.02 crores, the share of Zydus Lifesciences Limited has reached an intraday high of Rs. 1,048.45 per equity share, rising nearly 5.78 percent from its previous day’s close price of Rs. 991.20. Since then, the stock has retreated and is currently trading at Rs. 1023.60 per equity share.
Q4 FY26 Result Walkthrough:
Coming into the quarterly results of Zydus Lifesciences Limited, the company’s consolidated revenue from operations increased by 16.22 percent YOY, from Rs. 6,527.9 crore in Q4 FY25 to Rs. 7,587 crore in Q4 FY26, and grew by 10.53 percent QoQ from Rs. 6,864.5 crore in Q3 FY26.
In Q4 FY26, Zydus Lifesciences Limited’s consolidated net profit increased by 8.68 percent YOY, reaching Rs. 1,272.5 crore compared to Rs. 1,170.9 crore during the same period last year. As compared to Q3 FY26, the net profit has increased by 22.11 percent, from Rs. 1,042.1 crore. The basic earnings per share increased by 8.68 percent and stood at Rs. 12.65 as against Rs. 11.64 recorded in the same quarter in the previous year, FY2025.
Dividend: Zydus Lifesciences Limited’s board of directors has recommended paying a final dividend at the rate of 100 percent on the face value of paid-up equity shares of Re. 1 each for the financial year 2025-26, which is a dividend of Re. 1 per equity share. The record date for this dividend is July 24, 2026.
Annual Performance of FY26:
Zydus Lifesciences Limited’s revenue has increased from Rs. 23,241.5 crore in FY25 to Rs. 27,148.4 crore in FY26, which has grown by 16.81 percent. The net profit has also grown by 11.37 percent from Rs. 4,525.5 crore in FY25 to Rs. 5,040 crore in FY26.
The annual basic earnings per share increased by 11.39 percent and stood at Rs. 50.09 as against Rs. 44.97 recorded in the financial year 2025.
Zydus Lifesciences Limited’s revenue and net profit have grown at a CAGR of 12.45 percent and 18.19 percent, respectively, over the last five years. In terms of return ratios, the company’s ROCE and ROE stand at 24.3 percent and 21.2 percent, respectively. Zydus Lifesciences Limited’s debt-to-equity ratio is 0.38x.
BuyBack:
Zydus Lifesciences Limited has announced a buyback of 95.65 lakh shares at Rs. 1,150 per share, which represents a premium of nearly 16 percent over the current market price of Rs. 991.20.
The total buyback size stands at around Rs. 1,100 crore, reflecting the company’s confidence in its long-term business outlook and financial strength. The buyback covers about 0.95 percent of the existing paid-up capital and is expected to improve shareholder value while also supporting investor sentiment in the near term.
Zydus Lifesciences Limited’s Buyback Record Date has been fixed as May 29, 2026, to determine the eligibility of equity shareholders entitled to participate in the proposed buyback offer.
Revenue Mix (FY26 & Q4 FY26):
In Q4 FY26, Zydus Lifesciences reported total revenue from operations of around Rs. 7,587 crore. The pharmaceuticals segment remained the key growth driver, contributing Rs. 5,776 crore, accounting for nearly 76 percent of total revenue. Consumer products generated Rs. 1,483 crore with a contribution of about 20 percent, while the medical technologies business added Rs. 328 crore, contributing close to 4 percent of quarterly revenue.
For the full year FY26, the company reported total revenue of around Rs. 27,148 crore. Pharmaceuticals continued to dominate the revenue mix with Rs. 22,412 crore, contributing nearly 83 percent of total revenue. Consumer products contributed Rs. 3,954 crore or around 15 percent, while the medical technologies segment added Rs. 782 crore, making up nearly 3 percent of the annual revenue mix.
Business Highlights:
Zydus Lifesciences has a strong global healthcare presence with over 29,000 employees, including more than 1,500 R&D scientists. The company operates 43 manufacturing sites capable of producing multiple dosage forms and has 8 research centers focused on APIs, generics, vaccines, biosimilars, and medical technologies. Zydus also owns 7 brands among India’s top 300 brands and ranks as the 3rd largest generic company in the US by prescriptions.
Company Overview:
Zydus Lifesciences Limited was founded in 1952 and is a leading Indian pharmaceutical and life sciences company headquartered in Ahmedabad, Gujarat. Formerly known as Cadila Healthcare Limited, it ranks among India’s top pharmaceutical manufacturers with operations spanning formulations, active pharmaceutical ingredients, vaccines, biosimilars, and wellness products.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
